Qurient Co. Ltd. announced that the company has entered into a clinical collaboration agreement with MSD, a tradename of Merck & Co., Inc., for clinical study of Q702, a triple inhibitor of Axl/Mer/CSF1R) in combination with MSD's anti-PD-1 therapy KEYTRUDA® (pembrolizumab). Under this agreement, Qurient will conduct a phase 1b/2 study in the U.S. and Korea to evaluate safety and efficacy of Q702 and KEYTRUDA in combination for the treatment of selected advanced solid tumors, including esophageal, gastric, hepatocellular, and cervical cancers.

Terms of the collaboration were not disclosed.